Results 131 to 140 of about 5,946,067 (288)

Remarkable Regression of an Osteolytic Lesion of Large Cell Lung Cancer Treated with Zoledronic Acid: A Case Report

Case Reports in Oncology, 2012
Zoledronic acid suppresses osteoclastic changes and reduces the risk of cancer-induced skeletal-related events. Moreover, it has been reported to have antitumor effects.
Sadayuki Kawai, Gengo Yamaura, Katsuhiro Yasuda, Takao Suzuki   +3 more
doaj   +1 more source

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis [PDF]

, 2021
Masashi Uehara, Yukio Nakamura, Takako Suzuki, Masaki Nakano, Jun Takahashi   +4 more
openalex   +1 more source

High Serum Concentration of Interleukine-6 and Rank-ligand as Risk Factors for Osteoporosis in Estrogen Deficiency Post-menopausal Women [PDF]

, 2009
Osteoporosis in post-menopausal women is not merely due to deficient estrogenhormone production. The development of osteoporosis is due to increased boneresorption by osteoclasts. The osteoclast\u27s number and activity is controlled by activatingfactors
Bakta, M. (Made), Kawiyana, K. S. (Ketut), Roeshadi, D. (Djoko), Surya, G. P. (Gusti)   +3 more
core  

Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers

Journal of Bone Oncology, 2017
Background: Bone is a metastatic site for various types of cancer. Cancer patients in whom bone metastases progress often have skeletal-related events (SREs).
Hiroo Imai, Ken Saijo, Hideharu Yamada, Kota Ohuchi, Yoshinari Okada, Keigo Komine, Masahiro Takahashi, Shin Takahashi, Masanobu Takahashi, Hideki Shimodaira, Chikashi Ishioka   +10 more
doaj   +1 more source

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

Health Technology Assessment, 2013
Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.
J Ford, E Cummins, P Sharma, A Elders, F Stewart, R Johnston, P Royle, R Jones, C Mulatero, R Todd, G Mowatt   +10 more
doaj   +1 more source

Delayed alveolar bone repair and osteonecrosis associated with Zoledronic Acid therapy in rats: macroscopic, microscopic and molecular analysis [PDF]

, 2020
Gustavo Zanna Ferreira, Edson Virgílio Zen Filho, Izabel Regina Fischer Rubira‐Bullen, Gustavo Pompermaier Garlet, Carlos Ferreira Santos, Paulo Sérgio da Silva Santos   +5 more
openalex   +1 more source

Zoledronic acid induced uveitis in multiple myeloma - A case report

, 2022
Anjana Devi Rudra Warrier
openalex   +1 more source

Zoledrinic Acid Induces Steoblastic Differentiation of Mesenchymal Stem Cells without Change in Hypomethylation Status of OSTERIX Promoter [PDF]

Cell Journal, 2012
Objective: Mechanism of zoledronic acid on osteoblastic differentiation of mesenchymal stem cells (MSCs) has not fully understood. With the knowledge of some drugs mechanism that alter methylation pattern of some genes, the present research sets out to ...
Maryam Mahmodinia Maymand, Saeid Kaviani, Masoud Soleimani, Yousef Mortazavi, Mehrdad Noruzinia, Majid Farshdousti Hagh   +5 more
doaj  

Biochemical Alterations Accompanied to Zoledronic Acid Treatment after High Doses of Vitamin D in Experimental Model

, 2020
Abdel Maksoud H.A, Mohamed G. Elharrif, Anwar K. R, Abdullah M.H, Nemer Alotaibi   +4 more
openalex   +1 more source

PDG43 SAFETY EVALUATION OF ZOLEDRONIC ACID AND DENOSUMAB USING FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) DATABASE 2012-2018 [PDF]

, 2019
Zizi Elsisi, Andrea Lin, J.J. Guo
openalex   +1 more source